QUOTED. 21 May 2019. Ian Crozier.
Medtronic PLC is encouraged by results of a 21-patient first in-human pilot study with its substernal Extravascular Implantable Cardioverter Defibrillator. See what the study's investigator Ian Crozier of Christchurch Hospital in New Zealand said about it here:
"This small but important study affirms the potential of this new extravascular approach to provide pacing and lifesaving defibrillation therapy without the risks that accompany transvenous leads implanted inside the heart and veins." -Ian Crozier, researcher, Christchurch Hospital
Click here for a free trial of Medtech Insight